Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients

Exclusion Criteria

• •Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)
• •Prior documented LVEF \< 40% or qualitative moderate or greater LV systolic dysfunction.
• •Current indication for statin therapy
• •Intolerance to statin therapy.
• •Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD, myocardial infarction, stroke)
• •Evidence of significant myocardial ischemia on stress testing at screening visit.
• •Evidence of hepatic abnormality (defined as liver enzymes \> 2 times the upper limit of normal values).
• •Uncontrolled hypertension (BP \> 150/100)
• •Significant valvular disease.
• •Atrial fibrillation
• •Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.
• •Restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).
• •Cor pulmonale or other cause of right heart failure not related to LV dysfunction.
• •Clinically significant pulmonary disease.
• •Pericardial constriction or hemodynamically significant pleural effusion.
• •Uncontrolled arrhythmia.
• •Any systemic condition other than heart failure that may limit survival to less than 2 years.
• •Advance renal disease (serum creatinine \> 3.0 mg/dl or on dialysis)
• •Known intolerance or allergy to HMG CoA reductase inhibitors
• •Uncontrolled hyper- or hypothyroidism.
• •Any subject characteristic that may interfere with study compliance, such as baseline dementia, substance abuse, history of non-compliance with medications or appointments.
• •Prisoners or other vulnerable populations.
• •Any woman of child-bearing age with a documented positive pregnancy test.
• •Subject is receiving therapy with other investigational therapy or is participating in any other clinical trial.